Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

The advent of immunotherapy has made an indelible mark on the field of cancer therapy,
especially the application of immune checkpoint inhibitors in clinical practice. Although …

Neoadjuvant ipilimumab+ nivolumab has demonstrated high pathologic response rates in
stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less …

The development and immune evasion of cancer stem cells (CSCs) limit the efficacy of
currently available anticancer therapies. Recent studies have shown that epigenetic …

The combination of targeted therapy with immune checkpoint inhibition (ICI) is an area of
intense interest. We studied the interaction of fibroblast growth factor receptor (FGFR) …

Human natural killer T (NKT) cells have been proposed as a promising cell platform for
chimeric antigen receptor (CAR) therapy in solid tumors. Here we generated murine CAR …

Pancreatic ductal adenocarcinoma (PDA) is characterized by low cytotoxic lymphocytes,
abundant immune-suppressive cells, and resistance to immune checkpoint inhibitors (ICI) …

HDAC3 is one of the main targets of histone deacetylase (HDAC) inhibitors in clinical
development as cancer therapies, yet the in vivo role of HDAC3 in solid tumors is unknown …

Simple Summary Immune checkpoint inhibitors (ICIs) are an important strategy in cancer
therapy. However, with the widespread clinical use of ICIs, people gradually found that ICIs …

Immunotherapy treatments harnessing the immune system herald a new era of personalized
medicine, offering considerable benefits for cancer patients. Over the past years, tumor …